Simple Summary Despite recent therapeutic advances against cancer, many patients do not
respond well or respond poorly, to treatment and develop resistance to more than one anti …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung
disease (ILD) of unknown aetiology, with a median survival of 2–4 years from the time of …

Fibroblasts in the tumor microenvironment have been proven to actively participate in tumor
progression; they can be “educated” by cancer cells acquiring an activated state and, as …

Non-small-cell lung cancer (NSCLC) is defined as the most universally diagnosed class of
lung cancer. Cisplatin (DDP) is an effective drug for NSCLC, but tumors are prone to drug …

The tumor microenvironment (TME) is a significant contributor to cancer progression
containing complex connections between cellular and chemical components and provides a …

Despite tremendous achievements in the field of targeted cancer therapy, chemotherapy is
still the main treatment option, which is challenged by acquired drug resistance. Various …

Objectives A cure for cancer is out of reach for most patients due to chemoresistance.
Cancer-associated fibroblasts (CAFs) play a vital role in cancer chemoresistance, but …

Physiological stress such as excessive reactive oxygen species (ROS) production may
contribute normal fibroblasts activation into cancer‑associated fibroblasts, which serve a …

The identification of new effective therapeutic options for non-small-cell lung cancer
(NSCLC) represents a crucial challenge in oncology. Recent studies indicate that cancer …

Purpose The cancer-associated fibroblasts (CAFs) are one of the most abundant
components of the tumor microenvironment (TME). CAFs have been implicated in tumor …